Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine compound containing febuxostat

A technology of febuxostat and composition, applied in the field of pharmaceutical composition containing febuxostat, capable of solving problems such as inability to obtain dissolution curve deviation

Active Publication Date: 2010-10-20
AVENTIS PHARMA HAINAN
View PDF3 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The patent of CN03806919 discloses a solid preparation containing a single crystal form, and it is mentioned that even the most stable crystal form cannot obtain a preparation with a small deviation of the dissolution curve

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine compound containing febuxostat
  • Medicine compound containing febuxostat
  • Medicine compound containing febuxostat

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017]

[0018] Preparation:

[0019] Dissolve povidone K30 and Tween-80 in a certain amount of ethanol as a binder; mix febuxostat with lactose and microcrystalline cellulose hypromellose, and add the above binder, Stir the formulation; dry at 40-60°C to obtain dry granules; granulate the dry granules with a granulator, add magnesium stearate, compress into tablets, coat with 15% Opadry water dispersion, pack, Instantly.

Embodiment 2

[0021]

[0022] Preparation:

[0023] Dissolve SDS in a certain amount of hot water, add starch to make 10% starch slurry as a binder; mix febuxostat with lactose, microcrystalline cellulose, and hydroxypropyl cellulose, and add the above Adhesive, stirring preparation; drying at 40-60°C to obtain dry granules; granulating the dry granules, adding magnesium stearate, tableting, coating with 15% Opadry water dispersion, packaging, that is have to.

Embodiment 3

[0025]

[0026]

[0027] Preparation:

[0028] Dissolve polyoxyethylene castor oil glyceryl ether (Cremophore EL) in a certain amount of purified water as a wetting agent; mix the prescribed amount of febuxostat with lactose, microcrystalline cellulose, and cross-linked carmellose sodium Then add the above wetting agent, stir the preparation; dry at 40-60°C to obtain dry granules; granulate the dry granules, add magnesium stearate, compress into tablets, and coat with 15% Opadry water dispersion. Pack and serve.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses a medicine compound containing febuxostat; and containing the febuxostat and surfactant, the medicine compound can be stably and quickly dissolved out and is applicable to arthrolithiasis curing.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing febuxostat, which is suitable for treating hyperuricemia. In particular, the formulations prepared with specific additives to enhance stability and febuxostat with small particles have stable and good dissolution rate, which can ensure the rapid and sufficient release of active ingredients. Background technique [0002] Gout is caused by the excessive production of uric acid in the body and the decline in the ability of the kidneys to clear it. Uric acid accumulates in the body, resulting in the precipitation of urate crystals in the joints and various organs. At present, the clinical treatment of gout drugs is mainly divided into promoting uric acid excretion and inhibiting uric acid production, and appropriate measures are taken to improve related symptoms. With the improvement of people's living standards, mainly the proportion of various animal foods in the diet structure is graduall...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/426A61K47/20A61K47/34A61K9/20A61P19/06A61K47/14
Inventor 尚丽霞
Owner AVENTIS PHARMA HAINAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com